Annexon, Inc. (ANNX)
NasdaqGS · USD · Healthcare · Biotechnology
$3.70 (-1.33%) as of
Key statistics
- Market cap
- 701.44M
- Forward P/E
- -3.45
- EPS (TTM)
- -1.1300
- Dividend yield
- 0.00%
- 52-week range
- 2.5400 – 7.1800
- Beta
- 1.33
- Profit margin
- 0.00%
- Analyst target
- $17.00
- Volume
- 2.65M
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Brisbane, CA, United States
- Employees
- 92
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.